Gilteritinib is a highly specific inhibitor of FLT3, AXL and anaplastic lymphoma kinase (ALK or CD246), exhibiting significant anti-leukemic activity in patients with R/R AML. This evidence concerns the gene AXL and acute myeloid leukemia.